Apolipoprotein A1 Infusions After Acute MI Disappoint in Phase III Trial

(MedPage Today) -- ATLANTA -- Plasma-derived human apolipoprotein A1 (CSL112) infusions failed to improve outcomes for acute myocardial infarction (MI) patients with multivessel coronary artery disease and other cardiovascular risk factors, the...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news